MedTrace Logo

Dalacin-T Gel Post Approval Study

NCT00219570 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2011-05-11

No results posted yet for this study

Summary

To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.

Conditions

  • Acne Vulgaris

Interventions

DRUG

clindamycin

DRUG

nadifloxacin

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • SACT INTERNATIONAL Co., LTD.

    collaborator UNKNOWN

  • Acronet

    collaborator INDUSTRY

  • Bellsystem24 , Inc.

    collaborator INDUSTRY

  • Mitsubishi Kagaku Bio-Clinical Laboratories, inc

    collaborator INDUSTRY

  • SATO Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2005-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219570 on ClinicalTrials.gov